To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
A crossover study in neuroimaging and genetics has linked genetic mutations to variations in the size of deep brain structures. This is a new step in evaluating the risk factors for developing a neurodegenerative disease.
Stanislas Dehaene, professor at the Collège de France and a researcher at the CEA-I2BM, has won the “Lire” prize for the best book of the year in the science category, for “Le code de la conscience” (The Code of Consciousness).
An international team involving the CEA-I2BM has just demonstrated that astrocytes induce the neuronal metabolism abnormalities that are characteristic of Huntington’s disease.
The rapid industrial success of carbon nanotubes raises questions about their impact on health and the environment. Researchers from the CEA and CNRS have developed a method to monitor these particles in the body, followed by observing their distribution after lung contamination. This study was published in ACS Nano.
By exploiting a large database of psychometric data and brain imaging, the Neurofunctional Imaging Group from Bordeaux has shown that the location of the brain’s language areas is independent of being right- or left-handed ... except for a very small fraction of left-handed people. This work was published in PLoS One on June 30, 2014.
Researchers from the CEA-IBITECS in collaboration with a team from the University of Strasbourg (UDS) have developed new reagents known as “chelating azides”, which can rapidly and selectively couple to any compound equipped with an alkyne group. The reaction can take place in any environment, including within a cell.
A team from the CEA-IBITECS participated in the identification of a novel role for an enzyme, the protease MMP-12, in the immune response to viral infection. The researchers developed an inhibitor of MMP-12, which enhances the immune response in a rodent model. This work, opens the way for the development of new antiviral therapies.
An Anglo-French team (AP-HP, Inserm, CEA/Mircen, UPEC, Oxford Biomedica, Cambridge University) coordinated by Professor Stéphane Palfi (head of the neurosurgery department at the hôpital Henri-Mondor) conducted a gene therapy trial in 15 patients with an advanced form of Parkinson’s disease.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.